$EYPT
EyePoint Pharmaceuticals, Inc.

2022 Q3 Form 10-Q Financial Statement

#000095017022015071 Filed on August 05, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $10.01M $11.57M $9.294M
YoY Change 10.52% 28.31% 26.97%
Cost Of Revenue $1.405M $1.734M $1.777M
YoY Change -23.01% -10.11% 27.84%
Gross Profit $8.607M $9.831M $7.517M
YoY Change 18.98% 38.78% 26.76%
Gross Profit Margin 85.97% 85.01% 80.88%
Selling, General & Admin $15.23M $15.44M $15.24M
YoY Change 13.35% 30.37% 41.46%
% of Gross Profit 176.93% 157.05% 202.75%
Research & Development $11.16M $12.99M $9.945M
YoY Change 31.35% 131.79% 81.51%
% of Gross Profit 129.69% 132.15% 132.3%
Depreciation & Amortization $615.0K $704.0K $81.00K
YoY Change -12.27% 3.23% 12.5%
% of Gross Profit 7.15% 7.16% 1.08%
Operating Expenses $28.41M $30.78M $27.58M
YoY Change 26.0% 53.97% 51.05%
Operating Profit -$18.40M -$19.22M -$18.28M
YoY Change 20.15% 75.03% 67.21%
Interest Expense $662.0K $552.0K $1.194M
YoY Change -147.9% -59.88% -11.29%
% of Operating Profit
Other Income/Expense, Net -$22.00K -$190.0K -$2.692M
YoY Change -98.41% -119.61% -269300.0%
Pretax Income -$18.42M -$19.41M -$20.98M
YoY Change 10.33% 93.87% 70.81%
Income Tax
% Of Pretax Income
Net Earnings -$18.42M -$19.41M -$20.98M
YoY Change 10.33% 93.87% 70.81%
Net Earnings / Revenue -183.98% -167.8% -225.69%
Basic Earnings Per Share -$0.49 -$0.52 -$0.56
Diluted Earnings Per Share -$0.49 -$0.52 -$563.1K
COMMON SHARES
Basic Shares Outstanding 34.07M 37.32M 37.25M
Diluted Shares Outstanding 37.34M 37.32M 37.25M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $157.3M $171.2M $190.8M
YoY Change 31.37% 34.11% 37.65%
Cash & Equivalents $75.36M $82.13M $101.5M
Short-Term Investments $81.90M $89.03M $89.24M
Other Short-Term Assets $10.44M $8.851M $5.920M
YoY Change 168.14% 138.96% 104.14%
Inventory $3.531M $3.254M $3.336M
Prepaid Expenses
Receivables $20.88M $22.59M $19.59M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $192.1M $205.9M $219.6M
YoY Change 35.5% 35.59% 37.78%
LONG-TERM ASSETS
Property, Plant & Equipment $1.015M $1.111M $545.0K
YoY Change -65.73% -61.26% -81.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $150.0K $150.0K $150.0K
YoY Change 0.0% 0.0% -25.0%
Total Long-Term Assets $28.39M $27.57M $24.93M
YoY Change 7.22% 2.11% -10.01%
TOTAL ASSETS
Total Short-Term Assets $192.1M $205.9M $219.6M
Total Long-Term Assets $28.39M $27.57M $24.93M
Total Assets $220.5M $233.4M $244.6M
YoY Change 31.05% 30.54% 30.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.112M $7.058M $7.302M
YoY Change -7.94% 30.2% 23.76%
Accrued Expenses $16.00M $14.31M $12.33M
YoY Change 39.61% 57.03% 108.44%
Deferred Revenue
YoY Change
Short-Term Debt $10.48M $10.48M $10.48M
YoY Change
Long-Term Debt Due $70.00K $105.0K $122.0K
YoY Change -52.38% 10.53% 22.0%
Total Short-Term Liabilities $34.26M $33.39M $31.97M
YoY Change 71.86% 105.48% 138.59%
LONG-TERM LIABILITIES
Long-Term Debt $29.25M $29.18M $29.13M
YoY Change -19.79% -19.55% -23.75%
Other Long-Term Liabilities $600.0K $600.0K $16.64M
YoY Change -96.86% -96.91% 608.95%
Total Long-Term Liabilities $29.85M $29.78M $45.77M
YoY Change -46.28% -46.54% 1849.94%
TOTAL LIABILITIES
Total Short-Term Liabilities $34.26M $33.39M $31.97M
Total Long-Term Liabilities $29.85M $29.78M $45.77M
Total Liabilities $84.14M $82.07M $77.74M
YoY Change 11.44% 14.05% 8.82%
SHAREHOLDERS EQUITY
Retained Earnings -$627.9M -$609.5M
YoY Change
Common Stock $763.6M $760.2M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $136.4M $151.4M $166.8M
YoY Change
Total Liabilities & Shareholders Equity $220.5M $233.4M $244.6M
YoY Change 31.05% 30.54% 30.68%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$18.42M -$19.41M -$20.98M
YoY Change 10.33% 93.87% 70.81%
Depreciation, Depletion And Amortization $615.0K $704.0K $81.00K
YoY Change -12.27% 3.23% 12.5%
Cash From Operating Activities -$13.14M -$19.12M -$20.16M
YoY Change 68.69% 81.4% 33.51%
INVESTING ACTIVITIES
Capital Expenditures -$1.198M -$218.0K $149.0K
YoY Change 814.5% 772.0%
Acquisitions
YoY Change
Other Investing Activities $7.470M $206.0K -$56.29M
YoY Change
Cash From Investing Activities $6.272M -$12.00K -$56.44M
YoY Change -4887.79% -52.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net $38.24M
YoY Change
Cash From Financing Activities 92.00K -276.0K -448.0K
YoY Change -4700.0% -27.75% -100.41%
NET CHANGE
Cash From Operating Activities -13.14M -19.12M -20.16M
Cash From Investing Activities 6.272M -12.00K -56.44M
Cash From Financing Activities 92.00K -276.0K -448.0K
Net Change In Cash -6.772M -19.41M -56.89M
YoY Change -14.49% 77.29% -160.73%
FREE CASH FLOW
Cash From Operating Activities -$13.14M -$19.12M -$20.16M
Capital Expenditures -$1.198M -$218.0K $149.0K
Free Cash Flow -$11.94M -$18.90M -$20.31M
YoY Change 55.93% 79.76% 34.49%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-90000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1354000
eypt Increase Decrease In Operating Lease Liabilities And Right Of Use Asset
IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset
-10000
eypt Increase Decrease In Operating Lease Liabilities And Right Of Use Asset
IncreaseDecreaseInOperatingLeaseLiabilitiesAndRightOfUseAsset
-74000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-423000
CY2022Q2 us-gaap Liabilities
Liabilities
82067000
CY2021Q4 us-gaap Liabilities
Liabilities
78992000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001314102
CY2022Q2 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2022Q2 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-421000
dei Amendment Flag
AmendmentFlag
false
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2022Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1860000
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2021Q4 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-51122
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
dei Entity Registrant Name
EntityRegistrantName
EyePoint Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-2774444
dei Entity Address Address Line1
EntityAddressAddressLine1
480 Pleasant Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34052616
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33905826
dei City Area Code
CityAreaCode
(617)
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.83
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
dei Local Phone Number
LocalPhoneNumber
926-5000
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-271000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7617000
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001
dei Trading Symbol
TradingSymbol
EYPT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
34071899
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
82134000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
178593000
CY2022Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
89033000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
32965000
CY2022Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
22594000
CY2021Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
18354000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8851000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4217000
CY2022Q2 us-gaap Inventory Net
InventoryNet
3254000
CY2021Q4 us-gaap Inventory Net
InventoryNet
3616000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
205866000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
237745000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1111000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
476000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4787000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2252000
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
21519000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
22749000
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
150000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
150000
CY2022Q2 us-gaap Assets
Assets
233433000
CY2021Q4 us-gaap Assets
Assets
263372000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
7058000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7385000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14312000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14422000
CY2022Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1137000
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1069000
CY2022Q2 us-gaap Short Term Borrowings
ShortTermBorrowings
10475000
CY2021Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
0
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
408000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
782000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
33390000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
23658000
CY2022Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
29181000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
36562000
CY2022Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
14070000
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
14560000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4826000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
151366000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
600000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2352000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
43000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34052616
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33905826
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
34000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
34000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
760209000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
752602000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-609479000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-569097000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
602000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
841000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
151366000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
184380000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
233433000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
263372000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11565000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9013000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
20859000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16336000
CY2022Q2 eypt Cost Of Sales Excluding Amortization Of Acquired Intangible Assets
CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets
1734000
CY2021Q2 eypt Cost Of Sales Excluding Amortization Of Acquired Intangible Assets
CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets
1929000
eypt Cost Of Sales Excluding Amortization Of Acquired Intangible Assets
CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets
3511000
eypt Cost Of Sales Excluding Amortization Of Acquired Intangible Assets
CostOfSalesExcludingAmortizationOfAcquiredIntangibleAssets
3319000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12992000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5605000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22937000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11084000
CY2022Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6883000
CY2021Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6659000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
13576000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
12318000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8557000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5184000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17106000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10299000
CY2022Q2 eypt Amortization Of Acquisition Cost Of Intangible Assets
AmortizationOfAcquisitionCostOfIntangibleAssets
615000
CY2021Q2 eypt Amortization Of Acquisition Cost Of Intangible Assets
AmortizationOfAcquisitionCostOfIntangibleAssets
615000
eypt Amortization Of Acquisition Cost Of Intangible Assets
AmortizationOfAcquisitionCostOfIntangibleAssets
1230000
eypt Amortization Of Acquisition Cost Of Intangible Assets
AmortizationOfAcquisitionCostOfIntangibleAssets
1230000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
30781000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
19992000
us-gaap Operating Expenses
OperatingExpenses
58360000
us-gaap Operating Expenses
OperatingExpenses
38250000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-19216000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10979000
us-gaap Operating Income Loss
OperatingIncomeLoss
-37501000
us-gaap Operating Income Loss
OperatingIncomeLoss
-21914000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
362000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
280000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
423000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
281000
CY2022Q2 us-gaap Interest Expense
InterestExpense
552000
CY2021Q2 us-gaap Interest Expense
InterestExpense
1376000
us-gaap Interest Expense
InterestExpense
1745000
us-gaap Interest Expense
InterestExpense
2722000
CY2022Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2021Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
2065000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1559000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
2065000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-190000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
969000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2881000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-376000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-19406000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-10010000
us-gaap Net Income Loss
NetIncomeLoss
-40382000
us-gaap Net Income Loss
NetIncomeLoss
-22290000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.52
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.52
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.35
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.83
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37322000
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37322000
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28744000
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28744000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37288000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37288000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26750000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26750000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-19406000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-10010000
us-gaap Net Income Loss
NetIncomeLoss
-40382000
us-gaap Net Income Loss
NetIncomeLoss
-22290000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-186000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-239000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19592000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10010000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40621000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22290000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
115707000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-10010000
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-12000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1180000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
106865000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
166819000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-19406000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-186000
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
20000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-21000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4140000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
18541000
us-gaap Net Income Loss
NetIncomeLoss
-22290000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
108403000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
173000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-140000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2168000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
106865000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
184380000
us-gaap Net Income Loss
NetIncomeLoss
-40382000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-239000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
20000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
201000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
40000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
151366000
us-gaap Profit Loss
ProfitLoss
-40382000
us-gaap Profit Loss
ProfitLoss
-22290000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1230000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1230000
us-gaap Depreciation
Depreciation
170000
us-gaap Depreciation
Depreciation
142000
eypt Amortization Of Debt Discount And Premium And Discount On Available For Sale Marketable Securities
AmortizationOfDebtDiscountAndPremiumAndDiscountOnAvailableForSaleMarketableSecurities
-4000
eypt Amortization Of Debt Discount And Premium And Discount On Available For Sale Marketable Securities
AmortizationOfDebtDiscountAndPremiumAndDiscountOnAvailableForSaleMarketableSecurities
300000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1559000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
2065000
us-gaap Share Based Compensation
ShareBasedCompensation
7617000
us-gaap Share Based Compensation
ShareBasedCompensation
2168000
us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
9310000
us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
5943000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-362000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39281000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25642000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
92087000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
36000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
367000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
25000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-56454000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-25000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
115666000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
30000000
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
573000
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
7263000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
38235000
us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
2294000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
21934000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
11459000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
271000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
140000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
241000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
183000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
67000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
58000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-724000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
108388000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-96459000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
82721000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
178743000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45059000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
82284000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
127780000
us-gaap Interest Paid Net
InterestPaidNet
1349000
us-gaap Interest Paid Net
InterestPaidNet
2403000
eypt Non Cash Unpaid Stock Issuance Costs
NonCashUnpaidStockIssuanceCosts
65000
eypt Non Cash Unpaid Debt Issue Costs
NonCashUnpaidDebtIssueCosts
26000
eypt Debt Instrument Exit Fee
DebtInstrumentExitFee
600000
eypt Payments Forgiven Under Paycheck Protection Program Loan
PaymentsForgivenUnderPaycheckProtectionProgramLoan
2041000
us-gaap Nature Of Operations
NatureOfOperations
<div style="text-indent:0.0%;font-size:0;margin-top:10.0pt;line-height:1.0925;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Operations</span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The accompanying condensed consolidated financial statements of EyePoint Pharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, the “Company”), as of June 30, 2022 and for the three and six months ended June 30, 2022 and 2021 are unaudited. Certain information in the footnote disclosures of these financial statements has been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”). These financial statements should be read in conjunction with the Company’s audited consolidated financial statements and footnotes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. In the opinion of management, these statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended December 31, 2021, and include all adjustments, consisting only of normal recurring adjustments, that are necessary for the fair presentation of the Company’s financial position, results of operations, comprehensive loss and cash flows for the periods indicated. The preparation of financial statements in accordance with United States (“U.S.”) generally accepted accounting principles (“GAAP”) requires management to make assumptions and estimates that affect, among other things, (i) reported amounts of assets and liabilities; (ii) disclosure of contingent assets and liabilities at the date of the consolidated financial statements; and (iii) reported amounts of revenues and expenses during the reporting period. The results of operations for the three months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the entire fiscal year or any future period.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company is a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders. The Company’s pipeline leverages its proprietary Durasert</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">®</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery anti-VEGF treatment initially targeting wet age-related macular degeneration (“wet AMD”), the leading cause of vision loss among people 50 years of age and older in the United States. The Company also has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> commercial products: YUTIQ</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">®</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, a once every three-year treatment for chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">®</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, a single-dose treatment for postoperative inflammation following ocular surgery. Both commercial products are currently being sold in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company plans to identify and advance additional pipeline product candidates through clinical and regulatory development. This may be accomplished through internal discovery efforts, research collaborations and/or in-licensing arrangements with partner molecules and potential acquisitions of additional ophthalmic products, product candidates or technologies that complement the Company’s current product portfolio.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Effects of the COVID-19 Coronavirus Pandemic</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The ongoing COVID-19 coronavirus pandemic (the “Pandemic”) has had a material and adverse impact on the Company’s business. The duration and full extent to which the Pandemic impacts the Company’s business, revenues, financial condition and cash flows depends on future developments that are highly uncertain, subject to change and are difficult to predict, including new information that may emerge concerning the Pandemic, and may cause intermittent or prolonged periods of reduced patient services at the Company’s customers’ facilities, which may negatively affect customer demand. The Company’s revenues, financial condition and cash flows may be adversely affected in the future as well. The Company is continuously monitoring the Pandemic and its potential effect on the Company’s financial position, results of operations and cash flows. This uncertainty could have an impact in future periods on certain estimates used in the preparation of the Company’s periodic financial results, including reserves for variable consideration related to product sales, realizability of certain receivables, assessment for excess or obsolete inventory and impairment of long-lived assets. Uncertainty around the extent and length of time of the Pandemic, and any future related financial impact cannot be reasonably estimated at this time.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Liquidity</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> The Company had cash, cash equivalents and investments in marketable securities of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">171.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million at June 30, 2022. The Company has a history of operating losses and has not had significant recurring cash inflows from revenue. The Company’s operations have been financed primarily from sales of its equity securities, issuance of debt and a combination of license fees, milestone payments, royalty income and other fees received from its collaboration partners. The Company anticipates that it will continue to incur losses as it continues the research and development of its product candidates and the Company does not expect revenues from its product sales to generate sufficient funding to sustain its operations in the near-term. The Company expects to continue fulfilling its funding needs through cash inflows from revenues of its product sales, licensing and research collaboration transactions, additional equity capital raises and other arrangements. The Company believes that its cash, cash equivalents and investments in marketable securities of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">171.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">at June 30, 2022 coupled with expected cash inflows from its product sales will enable the Company to fund its current and planned operations for at least the next twelve months from the date these consolidated financial statements were issued. Actual cash requirements could differ from management’s projections due to many factors, including the continued effect of the Pandemic on the Company’s business and the medical community, the timing and results of the Company’s</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">clinical </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">trials for EYP-1901, additional investments in research and development programs, the success of ongoing commercialization efforts for YUTIQ and DEXYCU, the actual costs of these ongoing commercialization efforts, competing technological and market developments and the costs of any strategic acquisitions and/or development of complementary business opportunities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Recently Adopted and Recently Issued Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">New accounting pronouncements are issued periodically by the Financial Accounting Standards Board (“FASB”) and are adopted by the Company as of the specified effective dates. The Company believes that recently issued and adopted pronouncements will not have a material impact on the Company’s financial position, results of operations and cash flows or do not apply to the Company’s operations.</span></p>
eypt Number Of Products
NumberOfProducts
2
CY2022Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
171200000
CY2022Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
171200000
CY2021Q4 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
3353000
eypt Contract With Customer Allowance For Credit Loss Additions
ContractWithCustomerAllowanceForCreditLossAdditions
10463000
eypt Contract With Customer Allowance For Deductions Applied And Payments Made
ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade
-9386000
CY2022Q2 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
4430000
CY2020Q4 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
1712000
eypt Contract With Customer Allowance For Credit Loss Additions
ContractWithCustomerAllowanceForCreditLossAdditions
5394000
eypt Contract With Customer Allowance For Credit Loss Increase Decrease
ContractWithCustomerAllowanceForCreditLossIncreaseDecrease
-172000
eypt Contract With Customer Allowance For Deductions Applied And Payments Made
ContractWithCustomerAllowanceForDeductionsAppliedAndPaymentsMade
-3931000
CY2021Q2 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
3003000
CY2022Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1946000
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2727000
CY2022Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
595000
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
405000
CY2022Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
713000
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
484000
CY2022Q2 us-gaap Inventory Net
InventoryNet
3254000
CY2021Q4 us-gaap Inventory Net
InventoryNet
3616000
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
68322000
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
68322000
CY2022Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
68322000
CY2021Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
68322000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
45573000
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
43113000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1230000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1230000
CY2022Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
46803000
CY2021Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
44343000
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
21519000
CY2021Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
23979000
us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P13Y
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
615000
CY2021Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
615000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1200000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1200000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4881000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7321000
CY2022Q2 eypt Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
2243000
CY2021Q4 eypt Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
753000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
505000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
712000
CY2022Q2 eypt Accrued Sales Chargebacks Rebates And Other Revenue Reserves
AccruedSalesChargebacksRebatesAndOtherRevenueReserves
3920000
CY2021Q4 eypt Accrued Sales Chargebacks Rebates And Other Revenue Reserves
AccruedSalesChargebacksRebatesAndOtherRevenueReserves
2974000
CY2022Q2 us-gaap Accrued Liabilities For Commissions Expense And Taxes
AccruedLiabilitiesForCommissionsExpenseAndTaxes
1837000
CY2021Q4 us-gaap Accrued Liabilities For Commissions Expense And Taxes
AccruedLiabilitiesForCommissionsExpenseAndTaxes
1518000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
926000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1144000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14312000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14422000
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y7M6D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.055
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
301000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
645000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4826000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1860000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
5127000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2505000
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
288000
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
213000
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
3000
CY2021Q2 us-gaap Variable Lease Cost
VariableLeaseCost
9000
us-gaap Operating Lease Expense
OperatingLeaseExpense
518000
us-gaap Operating Lease Expense
OperatingLeaseExpense
427000
us-gaap Variable Lease Cost
VariableLeaseCost
6000
us-gaap Variable Lease Cost
VariableLeaseCost
18000
CY2022Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
238000
CY2021Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
221000
us-gaap Operating Lease Payments
OperatingLeasePayments
480000
us-gaap Operating Lease Payments
OperatingLeasePayments
442000
CY2022Q2 eypt Finance Lease Property And Equipment Gross
FinanceLeasePropertyAndEquipmentGross
270000
CY2021Q4 eypt Finance Lease Property And Equipment Gross
FinanceLeasePropertyAndEquipmentGross
371000
CY2022Q2 eypt Finance Lease Accumulated Amortization Property And Equipment
FinanceLeaseAccumulatedAmortizationPropertyAndEquipment
172000
CY2021Q4 eypt Finance Lease Accumulated Amortization Property And Equipment
FinanceLeaseAccumulatedAmortizationPropertyAndEquipment
205000
CY2022Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
98000
CY2021Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
166000
CY2022Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
105000
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
137000
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
36000
CY2022Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
105000
CY2021Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
173000
CY2022Q2 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
34000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
68000
CY2022Q2 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
4000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
8000
CY2022Q2 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
4000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
8000
CY2022Q2 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
34000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
67000
CY2021Q2 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
30000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
62000
CY2021Q2 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
4000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
10000
CY2021Q2 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
4000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
10000
CY2021Q2 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
29000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
58000
CY2022Q2 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P0Y9M18D
CY2022Q2 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.125
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
348000
CY2022Q2 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
73000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
701000
CY2022Q2 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
37000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1073000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1113000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1158000
CY2022Q2 eypt Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
1699000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6092000
CY2022Q2 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
110000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
965000
CY2022Q2 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
5000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
5127000
CY2022Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
105000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
9167000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
10000000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
10000000
CY2022Q2 eypt Long Term Debt Maturities Repayments Of Principal After Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour
833000
CY2022Q2 us-gaap Long Term Debt
LongTermDebt
30000000
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
48683
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
12.33
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
48683
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
12.33
CY2022Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
48683
CY2022Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
12.33
CY2021Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
48683
CY2021Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
12.33
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4140000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1180000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7617000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2168000
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
17100000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M
CY2022Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
89000000.0
CY2021Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
155600000
CY2021Q4 us-gaap Commercial Paper At Carrying Value
CommercialPaperAtCarryingValue
16500000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
33000000.0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4661244
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2450203

Files In Submission

Name View Source Status
0000950170-22-015071-index-headers.html Edgar Link pending
0000950170-22-015071-index.html Edgar Link pending
0000950170-22-015071.txt Edgar Link pending
0000950170-22-015071-xbrl.zip Edgar Link pending
eypt-20220630.htm Edgar Link pending
eypt-20220630.xsd Edgar Link pending
eypt-20220630_cal.xml Edgar Link unprocessable
eypt-20220630_def.xml Edgar Link unprocessable
eypt-20220630_htm.xml Edgar Link completed
eypt-20220630_lab.xml Edgar Link unprocessable
eypt-20220630_pre.xml Edgar Link unprocessable
eypt-ex10_1.htm Edgar Link pending
eypt-ex10_2.htm Edgar Link pending
eypt-ex10_3.htm Edgar Link pending
eypt-ex31_1.htm Edgar Link pending
eypt-ex31_2.htm Edgar Link pending
eypt-ex32_1.htm Edgar Link pending
eypt-ex32_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending